Mabion (272.F) traded down -3.49 % during a 24 hours period ending at 02:02 AM Central Europe on Tuesday 27th. One Mabion stock can currently be bought for about PLN 8 on popular exchanges. Current supply of Mabion stocks is 16.2 mn. Mabion has a current market capitalization of PLN 129.8 mn and approximately PLN 271.7 k worth of Mabion was traded on exchanges in the last 24 hours. Since last month end, Mabion has traded 3.21 % up. Simple moving average of last 200 days is at PLN 7.91. The highest price of past 52 weeks was recorded at PLN 10 on 03/16/2026. 52 weeks low was at PLN 6.7 on 12/19/2025.

Here is how related stocks have performed in the past 24 hours:

  • Bowim (Z39.F) traded up 0.59 % and now trades at PLN 7. Bowim has a market capitalisation of PLN 115.9 mn. Bowim has a current price to earnings ratio of 5.55.

  • Zaklady Magnezytowe Ropczyce (QL7.F) traded down -2.59 % and now trades at PLN 22.8. Zaklady Magnezytowe Ropczyce has a market capitalisation of PLN 126 mn. Zaklady Magnezytowe Ropczyce has a current price to earnings ratio of 6.85.

  • Sfd (7PQ.F) traded up 1.67 % and now trades at PLN 3.1. Sfd has a market capitalisation of PLN 133.9 mn. Current price/earnings ratio for Sfd is 20.72.

  • Aqua (9S0.F) traded up 2.68 % and now trades at PLN 11.5. Aqua has a market capitalisation of PLN 149.4 mn. Current price/earnings ratio for Aqua is 13.85.

  • M4b (24D.F) traded up 6.67 % and now trades at PLN 16. Current market capitalisation for M4b is PLN 118.7 mn.

About Mabion

Mabion SA is a biotechnology company based in Poland that researches and develops biotechnology and biosimilar drugs to treat various diseases, including cancer, autoimmune, and metabolic conditions. The company specializes in the development of several drugs, such as MabionCD20 for the treatment of lymphomas and leukemia blood cancers, rheumatoid arthritis; MabionHER2 for the treatment of breast cancer; and MabionVEGF_Fab for the treatment of various eye diseases in adults. Additionally, Mabion S.A. develops MabionEGFR for the treatment of metastatic colorectal cancer and MabionVEGF for the treatment of colon or rectal cancer, metastatic breast cancer, and metastatic or recurrent lung cancer with other anticancer drugs. The company was founded in 2007 and has its main office in Konstantynow Lodzki, Poland.